



CONSOLIDATED REPORT OF THE 1ST SEMESTER OF 2019

Board of Administrators of Farmaceutica REMEDIA S.A.

Farmaceutica REMEDIA S.A.

Registered office: Deva 330160, No. 43 Dorobantilor Street, Hunedoara County, telephone/fax: + 40 254 223 260

Operational office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, telephone/fax: + 40 213 211 640

remedia@remedia.ro, www.remedia.ro

Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 10,608,980

IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

**Consolidated REPORT of the 1st semester of 2019
according to the F.S.A. Regulation No. nr. 5/2018**

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **Lei 10.608.980**
Paid-up share capital: **Lei 10.608.980**
Registered office: **DEVA, No. 43 Dorobanților Street, PC
330160**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration:
with the Trade Register Office: **J20/700/25.07.1991**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(Registration certificate No. 1470/04.05.2009)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **Lei 0,10**
Position in RNSC Register: **1636**
Total number: **106.089.800**
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010,70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
	TOTAL	106.089.800	10.608.980,00 Lei

Organised market on which securities are traded:

Bucharest Stock Exchange – Standard category

The total market value as at 8.08.2019 is of 39.889.764,8 Lei

The value of a RMAH share is of 0,376 Lei. (as at 08.08.2019)

1. Important events to report

During the period 01.01.2019 – 30.06.2019 there were no important events that have a particular impact on the financial position of the company Farmaceutica REMEDIA S.A.

2. The general description of the financial position and of the issuer's performances and of its branches afferent to the 1st semester of 2019

During the period 01.01.2019 – 30.06.2019 the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations during January-June 2019 (Lei)	Realisations during January – June 2018 (Lei)**	Evolution 2019/2018 (%)
1.	Net sales of goods *	209.213.158	209.781.696	- 0,28
2.	Other operating revenues	3.236.434	2.520.858	+ 28,39
3.	Total operating income	212.449.592	212.302.554	+ 0,07
4.	Total operational costs *	209.705.675	209.587.161	+ 0,06
5.	Operating result	2.743.917	2.715.393	+ 1,05
6.	Financial result	-374.430	-19.849	- 1.786,4
7.	Gross result	2.369.486	2.695.544	- 12,1

* Including trade discounts granted/received

**The values were retreated according to IFRS16

A breakdown of sales of goods by segment of activity is presented as follows:

Lei

REMEDIA Pharmacies	51.608.206	24,57%
Distribution	100.009.474	47,61%
Hospitals & Private Clinics Distribution	46.884.597	22,31%
Other operations	11.567.194	5,51%
Total	210.069.471	100,00 %

“Other operating revenues” mainly comprise the following categories of revenues:

- collected rents
- marketing services
- sale of assets
- logistic services

- other services

3. The financial statements as at 30.06.2019 were not audited by the independent financial auditor.

4. Economic-financial indicators as at 30.06.2019

LIQUIDITY AND WORKING CAPITAL	FR	FRDL
Afferent liquidity (Current assets/ current debts)	1,15	0,99
Current assets	29.846.239	201.316.712
Current debts	25.867.962	202.198.461
Indebtedness degree (loaned capital/equity x 100)	0%	372,2%
Loaned capital*	0	15.851.873
Equity	40.555.712	4.259.028
Turnover speed for client debit items (Average customer balance /turnover*180x)	43 days	128 days
Average customer balance	12.640.848	137.668.149
Net turnover	52.740.570	194.078.292
Turnover speed of stocks (average stock/ net COGS)*180	66 days	74 days
Average stock	14.803.785	72.984.402
Net COGS	40.659.908	178.021.684

*including financial leasing

Notes:

1) Current liquidity – In the case of FR, the indicator level reflects a good payment capacity, therefore a low risk for creditors, certifying that the company is able to cover its short-term debts based on receivables and cash availability. The indicator positively evolved as compared to the same period of last year (1,1) although it declined slightly as compared to March 2019 (1,19). In the case of FRDL, the indicator is at the attention limit, regressing both as compared to the same period of last year (1,01) and as compared to the first quarter of 2019 (1,02)

2) Indebtedness degree expresses the effectiveness of credit risk management, indicating potential funding, liquidity problems, with influences in meeting the commitments. In the case of FR there is no risk while for FRDL, the value of the indicator indicates an average risk. In calculating this indicator, the borrowed capital comprises both bank loans and finance lease liabilities.

3) Turnover speed for client debit items expresses the effectiveness of the company in collecting its claims, i.e. the number of days until the debtors pay their debts to the company. Considering the dynamics of sales and the specificity of receivables collections in the distribution of drugs, we believe that the indicator's value is a normal one for both companies, in the given circumstances.

The dynamics of this indicator was for FR the following: 46 days for the first semester of 2018, 42 days for the 1st quarter of 2019 and 43 days for the 1st semester of 2019. In the case of FRDL, we have: 111 days for the first semester of 2018, 131 days in the 1st quarter of 2019 and 128 days in the first semester of 2019.

⁴⁾ **The days on hand** indicator value (66 respectively, 47 days) can be considered to fall within the activity specificity, exceeding the limit imposed by the internal procedures of the company (45 days) in the case of FR. The indicator had the same value, both on 31.03.2019 and on 30.06.2018. If the FR indicator was strongly degraded as compared to the same period of last year (47 days), being maintained at approximately the same level as compared to the first quarter of 2019 (76 days)

Chairman of the Board of Administrators – „TARUS” – Valentin Norbert Tarus e.U.